raised US $40 million through the private placement of approximately 13,724,000 shares of its common stock to new pharmaceutical and financial investors. The proceeds will be used to fund the ongoing development of ENB-0040, Enobia's enzyme replacement therapy (ERT) for hypophosphatasia, a rare and potentially life threatening genetic bone disorder for which there is no currently approved therapy.
I am replying to the Shire post because I am wondering if this company gets acquired before going public... Rare genetic disorder, no other treatments, ERT. I could think of a good buyer
AI
